Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRQN21
|
|||
| Drug Name |
ZN-c3
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Uterine serous carcinoma [ICD-11: 2C72.1] | Phase 2 | [1] | |
| Company |
Zentalis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Wee1-like protein kinase (WEE1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell cycle | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | PLK1 signaling events | |||
| Reactome | Polo-like kinase mediated events | |||
| Cyclin E associated events during G1/S transition | ||||
| Cyclin A/B1 associated events during G2/M transition | ||||
| G2/M DNA replication checkpoint | ||||
| Cyclin A:Cdk2-associated events at S phase entry | ||||
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | ||||
| Factors involved in megakaryocyte development and platelet production | ||||
| WikiPathways | G1 to S cell cycle control | |||
| S Phase | ||||
| Retinoblastoma (RB) in Cancer | ||||
| Integrated Breast Cancer Pathway | ||||
| Mitotic G2-G2/M phases | ||||
| Mitotic G1-G1/S phases | ||||
| Factors involved in megakaryocyte development and platelet production | ||||
| Cell Cycle | ||||
| Cell Cycle Checkpoints | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04814108) A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.